Yannick Bulliard

Yannick Bulliard

Company: Immatics

Job title: Director, Translational Science

Bio:

Yannick Bulliard joined Immatics, TX in 2016, where he is leading the development of the company’s preclinical cell therapy portfolio. In addition, he oversees the scientific development of ACTallo®, Immatics’ take on off-the-shelf TCR-T therapy. Prior to Immatics, Dr. Bulliard worked at Amgen, CA, where he was responsible for the development of key strategic preclinical assets in Immuno-Oncology. Dr. Bulliard obtained his Ph.D. from the Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland and followed by a postdoctoral fellowship at the Novartis Institute for Biomedical Research (NIBR), MA.

 

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.